New hope for Hard-to-Treat myeloma: QLS32015 enters phase 3 trial

NCT ID NCT07138209

Recruiting now Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called QLS32015 against two standard treatment combinations (pomalidomide with dexamethasone or selinexor with dexamethasone) in 228 people with multiple myeloma that has relapsed or is refractory. The main goal is to see if QLS32015 can delay cancer progression better than the current options. Participants are randomly assigned to receive either the new drug or one of the standard regimens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLS32015
What this could lead to: If successful, QLS32015 could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not be more effective or safer than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

National Clinical Research Center for Blood Diseases
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.